A Pilot Study of F-18 Fluciclovine-PET/CT as A Diagnostic Tool for Bone Metastases in Patients With Hormonal Sensitive and Resistant Prostate Adenocarcinoma

Condition: Prostate Adenocarcinoma


  • Diagnostic Test: F-18 fluciclovine-PET/CT scan

Purpose: Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03496844

Sponsor: University of Arizona

Primary Outcome Measures:

  • Measure: True positive and false positive rate of positive bone findings on F-18 fluciclovine-PET/CT scan compared to gold standard of bone biopsy
  • Time Frame: 3 years
  • Safety Issue:

Estimated Enrollment: 20

Study Start Date: April 15, 2018


  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  1. Male
  2. Be ≥ 18 years of age
  3. Diagnosed with prostate cancer
  4. Be willing and able to provide informed consent
  5. Be informed of the investigational nature of this study

Exclusion Criteria:

  1. Having a history of severe claustrophobia
  2. Weight exceeding 400lbs


  • Carol Stuehm
  • 5206268318


  • University of Arizona
  • Tucson Arizona 85724 United States

View trial on ClinicalTrials.gov


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.